Literature DB >> 24360225

Urate oxidase should remain mandatory in patients at high risk of tumor lysis syndrome.

Michael Darmon1, Aurelie Bourmaud2, François Vincent3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24360225     DOI: 10.1053/j.ajkd.2013.06.029

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  1 in total

1.  Febuxostat and tumor lysis syndrome: an indication that remains unclear.

Authors:  F Vincent; A Dupré; C Mousseaux; C Bornstain; M Darmon
Journal:  Int J Clin Oncol       Date:  2016-12-01       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.